Pharma Mar (FRA:PMRA) EPS (Basic): €4.39 (TTM As of Mar. 2026)


FRA:PMRA Pharma Mar SA FRA:PMRA
83 GF Score
Price €68.05
GF Value €83.37
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Pharma Mar EPS (Basic)?

Pharma Mar FRA:PMRA -1.80% 83 EPS (Basic) is €4.39 as of Mar. 2026. GuruFocus rates FRA:PMRA with a GF Score™ of 83/100 and a GF Value™ of €83.37 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Pharma Mar's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was €0.09. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was €4.39.

Pharma Mar's EPS (Diluted) for the three months ended in Mar. 2026 was €0.09. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €4.39.

Pharma Mar's EPS without NRI for the three months ended in Mar. 2026 was €0.09. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 4.36.

During the past 12 months, Pharma Mar's average EPS without NRIGrowth Rate was 223.50% per year. During the past 3 years, the average EPS without NRI Growth Rate was 14.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was -26.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Pharma Mar's highest 3-Year average EPS without NRI Growth Rate was 48.20% per year. The lowest was -81.40% per year. And the median was -0.60% per year.

Pharma Mar  (FRA:PMRA) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Pharma Mar EPS (Basic) Related Terms

Pharma Mar EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Pharma Mar's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharma Mar EPS (Basic) Chart

Pharma Mar Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.14 2.73 0.06 1.49 4.30

Pharma Mar Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.23 1.34 -0.24 3.20 0.09
FRA:PMRA
83GF Score
Pharma Mar SA FRA:PMRA
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharma Mar EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Pharma Mar's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(74.986-0)/17.431
=4.30

Pharma Mar's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(1.533-0)/17.306
=0.09

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €4.39 mean?
Pharma Mar (FRA:PMRA) has a EPS (Basic) of €4.39 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Pharma Mar and its competitors.
Is Pharma Mar's EPS (Basic) too high?
Pharma Mar's current EPS (Basic) is €4.39. Overall, Pharma Mar has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma Mar's EPS (Basic) compare to VRTX and REGN?
Pharma Mar's EPS (Basic) of €4.39 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Pharma Mar and its competitors. Pharma Mar's current EPS (Basic) is €4.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Mar stock overvalued right now?
Based on GuruFocus' analysis, Pharma Mar (FRA:PMRA) is currently considered Modestly Undervalued. The stock's GF Value™ is €83.37, compared to a current price of €68.05 — trading 18.4% below its estimated fair value. The current EPS (Basic) is €4.39. Pharma Mar's overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Pharma Mar (FRA:PMRA), the current EPS (Basic) is €4.39 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharma Mar (FRA:PMRA) Overvalued in 2026?

Based on GuruFocus' analysis, Pharma Mar stock appears to be undervalued. The current stock price of €68.05 is trading 18.4% below its estimated GF Value™ of €83.37. GuruFocus considers Pharma Mar to be Modestly Undervalued.

Key valuation signals for FRA:PMRA:

  • EPS (Basic): €4.39
  • GF Value™: €83.37 vs. price of €68.05 (18.4% below fair value)
  • GF Score™: 83/100 with 3 warning signs

No single metric tells the full story. See the FRA:PMRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharma Mar Business Description

Address Avenida de los Reyes, 1, Poligono Industrial La Mina-norte, Colmenar Viejo, Madrid, ESP, 28770
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
83GF Score

Get the complete analysis for FRA:PMRA

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€68.05
Price
€83.37
GF Value